Notice2026-08378
Advisory Committee; Pharmacy Compounding Advisory Committee; Renewal
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
April 30, 2026
Issuing agencies
Health and Human Services DepartmentFood and Drug Administration
Abstract
The Food and Drug Administration (FDA or the Agency) is announcing the renewal of the Pharmacy Compounding Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Pharmacy Compounding Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the April 25, 2028, expiration date.
Full Text
<html>
<head>
<title>Federal Register, Volume 91 Issue 83 (Thursday, April 30, 2026)</title>
</head>
<body><pre>
[Federal Register Volume 91, Number 83 (Thursday, April 30, 2026)]
[Notices]
[Pages 23275-23276]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2026-08378]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2026-N-0008]
Advisory Committee; Pharmacy Compounding Advisory Committee;
Renewal
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice; renewal of Federal advisory committee.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or the Agency) is
announcing the renewal of the Pharmacy Compounding Advisory Committee
by the Commissioner of Food and Drugs (the Commissioner). The
Commissioner has determined that it is in the public interest to renew
the Pharmacy Compounding Advisory Committee for an additional 2 years
beyond the charter expiration date. The new charter will be in effect
until the April 25, 2028, expiration date.
DATES: The current charter for the Pharmacy Compounding Advisory
Committee will expire on April 25, 2026, unless the Commissioner
formally determines that renewal is in the public interest.
FOR FURTHER INFORMATION CONTACT: Advisory Committee Oversight and
Management Staff, Office of the Chief Scientist, Food and Drug
Administration, 10903 New Hampshire Ave., Bldg. 1, Rm. 3215, Silver
Spring, MD 20993-0002, (301) 796-8220, <a href="/cdn-cgi/l/email-protection#773634383a242402151a1e04041e18190437111316591f1f0459101801"><span class="__cf_email__" data-cfemail="befffdf1f3ededcbdcd3d7cdcdd7d1d0cdfed8dadf90d6d6cd90d9d1c8">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: FDA is announcing the renewal of the
Pharmacy Compounding Advisory Committee (the Committee). The Committee
is a non-discretionary Federal advisory committee established to
provide advice to the Commissioner. The Committee advises the
Commissioner or designee in discharging responsibilities as they relate
to compounding drugs for human use and, as required, any other product
for which FDA has regulatory responsibility.
The Committee shall provide advice on scientific, technical, and
medical issues concerning drug compounding under sections 503A and 503B
of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353a and 353b),
and, as required, any other product for which FDA has regulatory
responsibility, and makes appropriate recommendations to the
Commissioner.
The Committee shall consist of a core of at least 10 voting members
including the Chair. Subject to legal and regulatory requirements,
members and the Chair are selected by and serve at the discretion of
the Commissioner or designee. Each member, including the Chair, will be
selected from among authorities knowledgeable in the fields of
pharmaceutical compounding, pharmaceutical manufacturing, pharmacy,
medicine, and related specialties. These members will include
representatives from the National Association of Boards of Pharmacy,
the United States Pharmacopeia, pharmacists with current experience and
expertise in compounding, physicians with background and knowledge in
compounding, and patient and public health advocacy organizations.
Members may be invited to serve for terms of up to four years, or
for less time in the discretion of the Commissioner or designee. Non-
Federal members of this committee will serve as Special Government
Employees or representatives. Federal members will serve as Regular
Government Employees or Ex-Officios. In addition to the voting members,
the Commissioner or designee may identify consumer and/or industry
representatives to join the Committee (or serve as alternate
representatives) as non-voting representative members(s), via a process
consistent with legal and regulatory requirements.
The Commissioner or designee shall have the authority to select
members of other scientific and technical FDA advisory committees to
serve temporarily as voting members and to designate Special Government
Employees to serve temporarily as voting members when: (1) expertise is
required that is not available among current voting standing members of
the Committee (when additional voting members are added to the
Committee to provide needed expertise, a quorum will be based on the
combined total of regular and added members), or (2) to comprise a
quorum when, because of unforeseen circumstances, a quorum is or will
be lacking. A quorum for the Committee is a majority of the current
voting members present at the time, provided that FDA may specify a
quorum that is less than a majority of the current voting members
because of the size of the Committee and the variety in the types of
issues that it will consider, or other reason determined appropriate in
accordance with legal and regulatory requirements. 21 CFR Sec.
14.22(d).
If functioning as a medical device panel, an additional non-voting
representative member of consumer interests and an additional non-
voting representative member of industry interests will be included in
addition to the voting members.
Further information regarding the most recent charter and other
information can be found at <a href="https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-charter">https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/pharmacy-compounding-advisory-committee-charter</a> or by contacting the Advisory Committee Oversight and
Management Staff (see FOR FURTHER INFORMATION CONTACT). In light of the
fact that no change has been made to the committee name or description
of duties, no amendment will be made to 21 CFR 14.100.
This notice is issued under the Federal Advisory Committee Act (5
U.S.C. app.). For general information related to FDA advisory
committees,
[[Page 23276]]
please visit us at <a href="http://www.fda.gov/AdvisoryCommittees/default.htm">http://www.fda.gov/AdvisoryCommittees/default.htm</a>.
Grace R. Graham,
Deputy Commissioner for Policy, Legislation, and International Affairs.
[FR Doc. 2026-08378 Filed 4-29-26; 8:45 am]
BILLING CODE 4164-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on April 30, 2026.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.